The Russo Brothers has shared artwork to celebrate ‘SPIDER-MAN: BRAND NEW DAY’ becoming the biggest domestic opening weekend of all time.
Passing ‘AVENGERS: ENDGAME’.
An 86 year old Pennsylvania farmer turned down a 15 million dollar offer from AI data center developers in order to preserve his family land.
For more than 60 years Mervin Raudabaugh has worked his 261 acre farm in Cumberland County Pennsylvania. The property is where he raised his family and maintained a thriving wildlife habitat. When developers approached him with an offer of more than 60 000 dollars per acre totaling over 15 million dollars he chose to reject it.
I was not interested in destroying my farms Raudabaugh said. Instead he sold his development rights to a land preservation program for just under 1.9 million dollars. This decision permanently protects the farmland woodlands and wetlands from future development.
His choice reflects a growing conflict across rural America as tech companies seek land for large scale AI data centers. These projects demand vast amounts of space electricity and water often leading to local resistance over the loss of agricultural land and environmental impacts.
While the financial incentives are substantial for many farming families Raudabaugh hopes his example encourages others to safeguard Americas farmland. For him protecting the land where future generations can live and enjoy its natural beauty was far more valuable than any monetary offer.
Clinicians described the results as “one of the most amazing things I’ve ever seen.” An experimental once-daily oral drug called daraxonrasib has produced unprecedented outcomes in advanced pancreatic cancer, reducing the risk of death by 60% compared to standard chemotherapy.
In the Phase 3 RASolute 302 trial, daraxonrasib, a RAS(ON) multi-selective inhibitor developed by Revolution Medicines, nearly doubled median overall survival from 6.6–6.7 months with chemotherapy to 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The trial, presented as a plenary session at the 2026 ASCO Annual Meeting, triggered a rare standing ovation from oncology experts.
Unlike traditional therapies, daraxonrasib effectively targets multiple KRAS variants and even wild-type RAS, offering broad applicability to the vast majority of pancreatic cancers. The drug was also far better tolerated, with only 1.2% of patients discontinuing treatment due to side effects, compared to 11.2% in the chemotherapy arm.
This represents a major advance for a disease long considered one of the most lethal in oncology. Experts are hailing daraxonrasib as a potential paradigm shift that could transform metastatic pancreatic cancer into a more manageable condition. The FDA has already granted expanded access for eligible patients.
[O’Reilly, E. M., et al. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. DOI: 10.1056/NEJMoa2605555]
The cast of 'Star Wars' (1977) 📷
Harrison Ford — Han Solo
David Prowse — Darth Vader
Peter Mayhew — Chewbacca
Carrie Fisher — Princess Leia
Kenny Baker — R2-D2
Mark Hamill — Luke Skywalker